A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

Summary

A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an adrenocorticotropic hormone \[ACTH\] receptor antagonist) in participants with ACTH-dependent Cushing's syndrome (Cushing's disease or Ectopic ACTH Syndrome \[EAS\])

Timeline

Start

2023-10-12

Primary completion

2026-10

Completion

2026-10

Drugs

Indications